GRAMD4

Across TCGA pan-cancer cohorts, GRAMD4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GRAMD4 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GRAMD4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GRAMD4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where GRAMD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.591	0.335	.016	4	view →
HNSC	DFS	Median	All	0.749	0.561	.022	2	view →
UCEC	DFS	Median	All	0.799	0.926	.037	2	view →
LSCC	OS	Median	All	1.000	0.936	.009	2	view →
GBM	DFS	Quartile	All	0.269	0.517	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GRAMD4–PDAC (OS)

Open the PDAC breakdown →